BRIEF — Hikma to sell biosimilar thrombosis drug in MENA region

London-listed Jordanian drugmaker Hikma Pharmaceuticals (LSE: HIK) has signed a licensing agreement with Spanish pharma firm Laboratorios Farmaceúticos Rovi (ROVI:SM) for its enoxaparin sodium biosimilar.

The original product, sold by Sanofi-Aventis under the names Lovenox, Clexane and others, is an anticoagulant that belongs to low molecular weight heparin class. It is used to treat and prevent deep vein thrombosis and pulmonary embolism. Rovi has achieved national authorization for its biosimilar of enoxaparin in 16 European markets.

Under the terms of the agreement, Hikma has the exclusive rights to distribute and market enoxaparin across its MENA markets.